Article
Bridging to transplant and post-transplant maintenance therapy with FLT3 inhibitors in patients with relapsed or refractory FLT3 mutated acute myeloid leukemia.
Hematology (Amsterdam, Netherlands) - 1 Dec 2023
Hirose Natsuki, Tachibana Takayoshi, Izumi Akihiko, Sato Shuku, Tadera Noriyuki, Tamai Yotaro, Kanamori Heiwa, Tanaka Masatsugu, Nakajima Hideaki
Abstract excerpt
OBJECTIVES AND METHODS: This single-center retrospective study was performed to evaluate the safety and efficacy of FMS-like tyrosine kinase 3 (FLT3) inhibitors before and after allogeneic hematopoietic cell transplantation (HCT) in relapsed/refractory patients with FLT3-mutation positive acute myeloid leukemia (AML). RESULTS: Ten patients who met the eligibility criteria were included. Eight of them achieved...
Topics
- Humans
- fms-Like Tyrosine Kinase 3
- Phenylurea Compounds
- Retrospective Studies
- Hematopoietic Stem Cell Transplantation
- Recurrence
- Mutation
- Leukemia, Myeloid, Acute
- Protein Kinase Inhibitors